CRESCENT BIOPHARMA, INC. (CBIO) Spending and interest coverage
- R&D / revenue · 12 months: Value 1284.79%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 124.62%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 1284.79% | Research and development expense / revenue. Period ending 2026-06-30. $152.67M ÷ $11.88M × 100 ≈ 1284.79% |
| Stock-based compensation / revenue · 12 months | 124.62% | Share-based compensation / revenue. Period ending 2026-06-30. $14.81M ÷ $11.88M × 100 ≈ 124.62% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 152.67M USD | Research and Development Expense |
| Revenue | 11.88M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 14.81M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -168.47M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $152.67M | $11.88M | $14.81M | $-168.47M | (m) | 1284.79% | 124.62% | (m) | (m) |
| 2026-03-31 | $145.36M | $11.88M | $16.18M | $-163.14M | (m) | 1223.28% | 136.19% | (m) | (m) |
| 2025-12-31 | $138.09M | $10.84M | $13.30M | $-152.63M | (m) | 1273.39% | 122.65% | (m) | (m) |
| 2025-09-30 | $43.29M | (m) | $9.72M | $-68.47M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $24.66M | (m) | $8.87M | $-53.82M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $8.25M | (m) | $3.91M | $-31.32M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $14.26M | (m) | $4.70M | $-40.04M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $19.31M | (m) | $4.45M | $-42.30M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $22.89M | (m) | $4.20M | $-40.88M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $20.68M | (m) | $3.85M | $-39.45M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $20.07M | (m) | $3.52M | $-39.28M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $20.67M | (m) | $3.52M | $-40.31M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $20.31M | (m) | $3.54M | $-39.26M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $24.21M | (m) | $3.65M | $-43.68M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $28.39M | (m) | $3.86M | $-47.40M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $35.40M | (m) | $4.28M | $-54.21M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $43.75M | (m) | $4.96M | $-62.78M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $45.95M | (m) | $5.55M | $-63.83M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $47.49M | (m) | $6.09M | $-63.45M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $46.32M | (m) | $6.39M | $-61.59M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $43.70M | (m) | $6.49M | $-57.98M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $43.41M | (m) | $6.69M | $-57.68M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $44.93M | (m) | $6.90M | $-51.51M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $44.68M | (m) | $7.00M | $-51.28M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $44.73M | (m) | $6.90M | $-51.65M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $47.92M | (m) | $6.65M | $-54.36M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $47.03M | (m) | $6.22M | $-61.39M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $47.60M | (m) | $5.64M | $-61.01M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $46.61M | (m) | $5.22M | $-59.43M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $42.84M | (m) | $4.85M | $-54.76M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $40.09M | (m) | $4.59M | $-51.50M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $34.77M | (m) | $4.40M | $-46.08M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $30.82M | (m) | $4.19M | $-41.74M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $27.24M | (m) | $4.03M | $-37.84M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $24.10M | (m) | $3.76M | $-33.93M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $23.44M | (m) | $3.52M | $-32.75M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $23.58M | (m) | $3.30M | $-32.46M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $23.64M | (m) | $3.08M | $-32.31M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $23.28M | $18.50K | $2.96M | $-31.91M | (m) | 125847.68% | 16025.77% | (m) | (m) |
| 2016-09-30 | $24.18M | $53.88K | (m) | $-32.44M | (m) | 44886.39% | (m) | (m) | (m) |
| 2016-06-30 | $23.30M | (m) | (m) | $-31.73M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $25.36M | (m) | (m) | $-13.25M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $25.05M | $20.07M | (m) | $-12.78M | (m) | 124.81% | (m) | (m) | (m) |
| 2015-09-30 | $23.37M | $20.04M | (m) | $-11.30M | (m) | 116.64% | (m) | (m) | (m) |
| 2015-06-30 | $23.38M | $20.04M | (m) | $-10.82M | (m) | 116.70% | (m) | (m) | (m) |
| 2015-03-31 | $20.90M | $15.03M | (m) | $-13.15M | (m) | 139.06% | (m) | (m) | (m) |
| 2014-12-31 | $19.57M | $15.03M | (m) | $-11.14M | (m) | 130.24% | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $11.70M | $3.99M | (m) | $-10.61M | (m) | 293.07% | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $9.44M | $15.26M | (m) | $3.64M | (m) | 61.86% | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |